DOCSLIB.ORG

Forum for Innovative Regenerative Medicine Members

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Forum for Innovative Regenerative Medicine Members Forum for Innovative Regenerative Medicine Ｍｅｍｂｅｒｓ As of Jun 9, 2021 Representative Director, Ken-ichiro Hata Japan Tissue Engineering Co., Ltd. Chairperson Representative Director, Yoshitsugu Shitaka Astellas Pharma Inc. Vice Chairperson Vice-chairpersons Shigeharu Nishiuchi Hitachi, Ltd. Tohru Hirose Novartis Pharma K.K. Directors Mikitomo Yasutake Asahi Kasei Corporation Setsuko Hashimoto CellSeed Inc. Toshiki Sugimoto Dai Nippon Printing Co., Ltd. Masayuki Yabuta Daiichi Sankyo Co., Ltd. Yutaka Yamaguchi FUJIFILM Corporation Masakazu Kobayashi iPS PORTAL, Inc. Yuji Sato JCR Pharmaceuticals Co., Ltd. Yoshifumi Torii Kyowa Kirin Co., Ltd. Takashige Kondo MEDINET Co., Ltd. Osamu Takahashi PHC Corporation Kazuya Omi SRL, Inc. Toru Kimura Sumitomo Dainippon Pharma Co., Ltd. Masanobu Kimura TAKARA BIO INC. Keiji Iwashita Takeda Pharmaceutical Company Limited Kazuhisa Senshu TERUMO CORPORATION Supervisory Cellth DeC Tadashi Sameshima Board Members Hironao Yazaki Ernst & Young ShinNihon LLC Regular Members Regular Members ADEKA CORPORATION Hitachi, Ltd. Advantec kensyusenta HITACHIZOSEN CORPORATION AGC Inc. Hyperion Drug Discovery Co., Ltd Airex Co.,Ltd. iHeart Japan Corporation AIRTECH JAPAN, LTD. IKARI SHODOKU CO.,LTD. AJINOMOTO CO., INC. Ikeda Scientific, Co., Ltd. Alfresa Holdings Corporation iPS Academia Japan, Inc. Anderson Mori & Tomotsune iPS PORTAL, Inc. AnGes, Inc. Ipsos Healthcare Japan Limited Asahi Kasei Corporation IQVIA Services Japan K.K. Astellas Pharma Inc. Iwatani Corporation bioMerieux Japan Ltd. Janssen Pharmaceutical K.K. BIOMIMETICS SYMPATHIES Inc. Japan Tissue Engineering Co., Ltd. BrightPath Biotherapeutics Co., Ltd. JCR Pharmaceuticals Co., Ltd. Celgene K.K. JMS CO,.LTD Cell Exosome Therapeutics JSR Corporation Cell Science & Technology Institute Inc. JTEC CORPORATION CellBank Corp. JUNTEN BIO Co.,Ltd. CellGenTech, Inc. Kaken Pharmaceutical Co., Ltd. CellSeed Inc. KANEKA CORPORATION CellSource Co., Ltd. KANTO CHEMICAL CO., INC. CHIYODA CORPORATION Kirin Holdings Company, Limited chromocenter Inc. Kohjin Bio Co., Ltd. Chugai Pharmaceutical Co., Ltd. KOKEN CO., LTD. CMIC Co., Ltd. KYOCERA Corporation CPC Corporation Kyokuto Pharmaceutical Industrial Co., Ltd. Cuorips Inc. KYORIN Pharmaceutical Co., Ltd. Cyfuse Biomedical K.K. Kyowa Kirin Co., Ltd. Dai Nippon Printing Co., Ltd. Life Science Institute, Inc. DAI-DAN CO,.LTD. Life Technologies Japan K.K. Daiichi Sankyo Co., Ltd. Lonza Japan Ltd. Denka Co., Ltd. Lymphocyte-bank Co.,Ltd. Earth Environmental Service Co., Ltd. Macrobiosis Inc. EPS Corporation MARUBISHI BIOENGINEERING Co., Ltd. ESPEC CORP. Maruho Co., Ltd. Eurofins Analytical Science Laboratories, Inc. MATRIXOME, Inc. FUJIFILM Corporation MEDINET Co., Ltd. FUJIFILM Wako Pure Chemical Corporation MEDIPAL HOLDINGS CORPORATION FUJISOFT INCORPORATED Megakaryon Corporation FUKOKU CO., LTD. Merck Ltd. Funakoshi Co.,Ltd. Metcela Inc. Gene Techno Science Co.,Ltd. METRAS, Inc. Grandsoul Research Institute for Immunology, Inc. MICRON Inc. HEALIOS K.K. micronix Co., Ltd. Heartseed Inc. Mitsubishi Chemical Corporation 1 Forum for Innovative Regenerative Medicine Ｍｅｍｂｅｒｓ As of Jun 9, 2021 Regular Members Regular Members MITSUBISHI GAS CHEMICAL COMPANY,INC. SANPLATEC CORP. MITSUBISHI LOGISTICS CORPORATION Saraya Co., Ltd. Mitsui Fudosan Co., Ltd. SAROUTE Co., Ltd. Mitsui-soko Holdings Co., Ltd. Sartorius Stedim Japan K.K. MIURA CO.,LTD SD Biosystem Co.,Ltd. MOCHIDA PHARMACEUTICAL CO., LTD. Seed Planning, Inc. Myoridge Co. Ltd. SEIKEN CO.,LTD. NanoCarrier Co.,Ltd. SHIBAMATA TRANSPORT Co.,Ltd. Nard institute, LTD. SHIBUYA KOGYO CO., LTD. Nexredge Inc. Shimadzu Corporation NICHIREI BIOSCIENCES INC. SHIMIZU CORPORATION NIKON CORPORATION Shin Nippon Biomedical Laboratories, Ltd. （SNBL) Nippi, Incorporated Shiseido Company, Limited Nippon Express Co.,Ltd. Showa Denko Materials Co., Ltd. NIPRO CORPORATION Sompo Japan Nipponkoa Insurance Inc. Nissan Chemical Corporation SRD Co., Ltd. NISSIN CORPORATION SRL, Inc. NISSUI PHARMACEUTICAL CO., LTD. Sumitomo Bakelite Co., Ltd. NITTA Corporation SUMITOMO CHEMICAL Co., Ltd. NOK Co. Sumitomo Dainippon Pharma Co., Ltd. North American Science Associates Japan G.K. SUZUKEN CO., LTD. Novartis Pharma K.K. SYSMEX CORPORATION NSK Ltd. TAIYO NIPPON SANSO Corporation Optima Inc. TAKARA BIO INC. Osaka Sanitary Co.,Ltd. Takeda Pharmaceutical Company Limited Otsuka Pharmaceutical Co., Ltd. Takenaka Corporation Otsuka Pharmaceutical Factory, Inc. Teijin Limited Panasonic Environmental Systems & Engineering Co., Ltd. TEIJIN PHARMA LIMITED PERSOL TEMPSTAFF CO.,LTD. Tella Pharma Inc. PeptiGrowth Inc. TERUMO CORPORATION Pfizer Japan Inc. Tokio Marine & Nichido Fire Insurance Co., Ltd. Pharma Solutions Co., Ltd. TOPPAN PRINTING CO., LTD. PharmaBio Corporation TOSOH CORPORATION PHC Corporation Toyo Seikan Group Holdings, Ltd. RAYMEI INC. Trust Express Co., Ltd. ReproCELL Inc. ＵｎｉＢｉｏ Ｃｏｒｐｏｒａｔｉｏｎ RION CO., LTD. Vision Care Inc. Roche Diagnostics K.K. VITAL KSK HOLDINGS, INC. ROHTO Pharmaceutical Co., Ltd. Wanbishi Archives Co., Ltd. SanBio Company Limited Yokogawa Electric Corporation SANKEN SETSUBI KOGYO CO.,LTD. ZENOAQ RESOURCE CO., LTD. SANKI Engineering Co., Ltd. ZIMMER BIOMET Special Members Special Members Central Institute for Experimental Animals Japan Blood Products Organization Foundation for Biomedical Research and Innovation at Kobe Japan Food Research Laboratories Supporting Members Supporting Members AIR LIQUIDE Kogyo Gas Ltd. Kondoh Industries, Ltd. ANTI-AGEING Co,.Ltd. KURARAY CO., LTD. B.BRAUN AESCULAP JAPAN CO., LTD. Mitsui Chemicals, Inc. COREFRONT Corporation MUTOH CO., LTD. Corning International K.K. Nikon CeLL innovation Co., Ltd. COSMO BIO CO., LTD. NIHON KOHDEN CORPORATION Cytori Therapeutics K.K. NIPPON SHOKUBAI Co.,LTD Daewoong Pharmaceutical Co., Ltd. Nobelpharma Co., Ltd. EELS(Edogawa Evolutionary Laboratory of Science) PAREXEL International Inc. Eil Inc. RICOH COMPANY, LTD. ERNST & YOUNG SHINNIHON LLC SCREEN Holdings Co., Ltd. Evonik Japan Co., Ltd. SEKISUI SEIKEI, LTD. FUJISOFT Tissue Engineering Co., Ltd. SHIN NIPPON AIR TECHNOLOGIES CO., LTD. Hitachi Plant Services Co., Ltd. SunFlare Co., Ltd. Human Life CORD Japan Inc. Takasago Thermal Engineering Co., Ltd. intellim Corporation TEC Project Services Corporation JTB Communication Design, Inc. TOMITA PHARMACEUTICAL CO.,LTD. KAN Research Institute, Inc. Toshiba Corporation Individual Members Individual Members Fuyuhiko Mori Mime Egami Fumiaki Hirata Naoki Watanabe Kenji Maekawa Rika Tanaka Masato Deguchi Zen-ichi Mohri Honorary Member Ｔoichi Ｔakenaka Yuzo Toda 2.
Load more

Recommended publications
  • Alma Eikoh Japan Large Cap Equity Fund a Sub-Fund of Alma Capital Investment Funds SICAV
    FOR PROFESSIONAL INVESTORS ONLY Alma Eikoh Japan Large Cap Equity Fund A sub-fund of Alma Capital Investment Funds SICAV As of 31 January 2020 Eikoh Fund description • Investment objective: seek long-term capital growth by investing generally in Japanese large cap stocks (with market capitalisation in excess of US$ 1bn) • Investment process: analyse long term company fundamentals through extensive in-house bottom up research with a strong risk management ethos • Portfolio of around 25-30 companies which are well managed, profitable and with good prospects. Portfolio managers believe that Cash Flow Return on Investment and value creation are key Investment manager: ACIM (Alma Capital Investment Management) • Alma Capital Investment Management is a Luxembourg based asset management company and holds a branch office in London • ACIM manages assets of $4bn and is regulated by the Luxembourg regulator the CSSF • The portfolio managers, led by James Pulsford, worked together at Eikoh Research Investment Management managing the portfolio before joining ACIM in January 2020 Cumulative performance (%) 1 M 3 M 6 M YTD 1Y 3Y ITD ITD (annualized) I GBP Hedged C shares -0.29 4.47 12.94 -0.29 24.54 26.44 86.03 11.36 I GBP C shares -0.58 2.63 4.95 -0.58 23.80 24.93 - - I EUR Hedged C shares -0.43 4.29 12.94 -0.43 23.69 23.44 - - I JPY C shares -0.35 4.53 13.85 -0.35 25.10 26.48 - - I EUR C shares 1.36 5.60 14.74 1.36 - - - - I EUR D shares 1.36 5.58 14.67 1.36 - - - - I USD Hedged C shares -0.20 5.06 14.81 -0.20 27.84 33.92 94.05 12.47 Topix (TR) -2.14 1.21 8.88 -2.14 10.17 18.46 53.20 7.86 Fund launched on 12 June 2014 (I USD Hedged C and I GBP Hedged C shares) Portfolio characteristics Performance (Indexed - Base 100) Main indicators Fund Index Alma Eikoh Japan Large Cap Equity Fund Topix TR No.
    [Show full text]
  • Research Paper Inter-Industry Innovations in Terms of Electric Mobility: Should Firms Take a Look Outside Their Industry?
    Inter-industry innovations in terms of electric mobility: Should firms take a look outside their industry? Research Paper Inter-industry innovations in terms of electric mobility: Should firms take a look outside their industry? Stephan von Delft* * University of Münster, Institute of Business Administration at the Department of Chemistry and Pharmacy, Leonardo-Campus 1, 48149 Münster, Germany, [email protected] The beginning electrification of the automotive powertrain is supposed to have a major impact on the automobile value chain - reshaping it significantly and brin- ging up new alliances, business models and knowledge bases. Such a transforma- tion of the value chain might fade boundaries between hitherto distinct knowled- ge bases, technologies, or industries. Over the past decades, the blurring of indus- try boundaries – the phenomenon of industry convergence – has gained attenti- on from researchers and practitioners. The anticipation of a convergence process plays an important role for strategic and innovation management decisions, e.g. for new business development, mergers and acquisitions or strategic partnerships. However, despite the relevance of convergence, it is often challenging for incum- bent firms to (1) foresee such a transformation of their environment, and (2) res- pond strategically to it. Hence, this study presents a tool to anticipate convergen- ce and strategic implications are discussed. 1 Introduction stitute rules of conducting business” (Hacklin et al., 2009, p. 723). Firms facing such a situation, thus Technological change is known as a key driver have to adapt to new knowledge bases and new of economic growth and prosperity (Schumpeter, technologies which do not belong to their former 1947; Abernathy and Utterback, 1978; Kondratieff, core competences or their traditional expertise 1979).
    [Show full text]
  • Nilotinib in Patients with Chronic Myeloid Leukemia: STAT2 Trial in Japan
    Haematologica HAEMATOL/2018/194894 Version 3 Haematologica HAEMATOL/2018/194894 Version 3 Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, and Hisashi Wakita Disclosures: 1. This study was supported by research funding from Novartis Pharmaceuticals to N.T. 2. N.T reports grants from Novartis Pharmaceuticals, during the conduct of the study; grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Otsuka, grants and personal fees from Pfizer, personal fees from Bristol-Myers Squibb, outside the submitted work; K.N reports grants from Zenyaku Kogyo Company, Limited, grants from Chugai Pharmaceutical, grants from Novartis Pharma K.K., grants from Kyowa Hakko Kirin Co, Ltd, grants from Nippon Shinyaku Co, Ltd, outside the submitted work; C.N reports personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Takeda pharmaceuticals, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Asahi Kasei Pharma, grants and personal fees from Shionogi, personal fees from Shire, personal fees from Jannsen, personal fees from Celgene, outside the submitted work; M.T. reports personal fees from Bristol-Myers Squib, personal fees from Pfizer, outside the submitted work; K.M reports grants from Kyowa Hakko Kirin Co.
    [Show full text]
  • OCTOBER 2020 PTAB Public Hearing Schedule
    OCTOBER 2020 PTAB Public Hearing Schedule Proceeding No. Serial No. PARTY Date Time 2020-004197 16043641 BIOGEN MA INC Thursday, October 1, 2020 9:00 AM (EDT) ALLERGAN PHARMACEUTICALS 2020-002635 13907447 Thursday, October 1, 2020 9:00 AM (EDT) INTERNATIONAL LIMITED 2020-002276 13612925 BAYER AG (MONSANTO) Thursday, October 1, 2020 9:00 AM (EDT) 2020-002277 13612929 OTSUKA PHARMACEUTICAL CO., 2020-002304 14341306 Thursday, October 1, 2020 9:00 AM (EDT) LTD. 2020-002327 15893354 CELLECTIS Thursday, October 1, 2020 9:00 AM (EDT) 2020-000258 15163285 POLY GROUP LLC Thursday, October 1, 2020 9:00 AM (PDT) 2020-000640 15414456 DISCERNDX INC. Thursday, October 1, 2020 9:00 AM (PDT) 2020-000934 13982470 DENOVO BIOMARKERS INC. Thursday, October 1, 2020 9:00 AM (PDT) THE BOARD OF TRUSTEES OF THE 2020-001247 15175848 LELAND STANFORD JUNIOR Thursday, October 1, 2020 9:00 AM (PDT) UNIVERSITY EDWARDS LIFESCIENCES 2020-001487 14563866 Thursday, October 1, 2020 9:00 AM (PDT) CORPORATION IKEDA FOOD RESEARCH COL LTD 2020-003630 16145178 Thursday, October 1, 2020 1:00 PM (EDT) and PHC CORPORATION 2020-002049 13310632 ADARE PHARMACEUTICALS INC. Thursday, October 1, 2020 1:00 PM (EDT) 2020-000053 13135898 OLEG ILLICH EPSHTEIN Thursday, October 1, 2020 1:00 PM (EDT) 2020-001829 15008646 MERZ PHARMA GMBH & CO. KGAA Thursday, October 1, 2020 1:00 PM (EDT) 2020-002360 15407037 IONIS PHARMACEUTICALS INC. Thursday, October 1, 2020 1:00 PM (EDT) 2020-002113 13729631 L'OREAL Thursday, October 1, 2020 1:00 PM (EDT) 2019-003658 13576565 QUNZHU LI and LI LI Thursday, October 1, 2020 1:00 PM (EDT) 2020-000322 14136660 CYTEC INDUSTRIES INC.
    [Show full text]
  • View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0
    Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively).
    [Show full text]
  • Acquisition of Printed Wiring Board Business of Showa Denko Materials Co., Ltd
    Polaris Capital Group Co., Ltd. June 7, 2021 Acquisition of Printed Wiring Board Business of Showa Denko Materials Co., Ltd. and Its Subsidiaries Polaris Private Equity Fund V, L.P., etc., managed by Polaris Capital Group Co., Ltd. (“Polaris”) have recently signed an agreement with Showa Denko Materials Co., Ltd. (“Showa Denko Materials”) to acquire all the shares outstanding of a new company (the “Newly-established Company”) established to succeed Printed Wiring Board (“PWB”) business operated by Showa Denko Materials and its subsidiaries (the “Target Business”). Based on its excellence in R&D and technical capabilities developed through its more than 50 years of operations in the global PWB market, Target Business offers a wide range of products with unique strengths, including ultra-high-density Multi Wiring Boards (“MWB”) (used for probe card for high- end DRAM testing) holding a dominant market share, high precision module PWB (used for RF module for 5G smartphone, etc.), Multilayer printed wiring Boards (“MLB”) for high-speed application (used for 400Gbps switch for data center, etc.), and aluminum-based PWB (used for automotive LED lighting, etc.). Target Business has won high customer satisfaction and therefore built strong relationships with leading players in various industries, leveraging its high yield rate and low defect rate, which are essential for winning in the high-end markets. Target Business maintains the leading position in the global PWB market backed by five manufacturing sites in Japan and Singapore, each of which
    [Show full text]
  • Published on July 21, 2021 1. Changes in Constituents 2
    Results of the Periodic Review and Component Stocks of Tokyo Stock Exchange Dividend Focus 100 Index (Effective July 30, 2021） Published on July 21, 2021 1. Changes in Constituents Addition（18） Deletion（18） CodeName Code Name 1414SHO-BOND Holdings Co.,Ltd. 1801 TAISEI CORPORATION 2154BeNext-Yumeshin Group Co. 1802 OBAYASHI CORPORATION 3191JOYFUL HONDA CO.,LTD. 1812 KAJIMA CORPORATION 4452Kao Corporation 2502 Asahi Group Holdings,Ltd. 5401NIPPON STEEL CORPORATION 4004 Showa Denko K.K. 5713Sumitomo Metal Mining Co.,Ltd. 4183 Mitsui Chemicals,Inc. 5802Sumitomo Electric Industries,Ltd. 4204 Sekisui Chemical Co.,Ltd. 5851RYOBI LIMITED 4324 DENTSU GROUP INC. 6028TechnoPro Holdings,Inc. 4768 OTSUKA CORPORATION 6502TOSHIBA CORPORATION 4927 POLA ORBIS HOLDINGS INC. 6503Mitsubishi Electric Corporation 5105 Toyo Tire Corporation 6988NITTO DENKO CORPORATION 5301 TOKAI CARBON CO.,LTD. 7011Mitsubishi Heavy Industries,Ltd. 6269 MODEC,INC. 7202ISUZU MOTORS LIMITED 6448 BROTHER INDUSTRIES,LTD. 7267HONDA MOTOR CO.,LTD. 6501 Hitachi,Ltd. 7956PIGEON CORPORATION 7270 SUBARU CORPORATION 9062NIPPON EXPRESS CO.,LTD. 8015 TOYOTA TSUSHO CORPORATION 9101Nippon Yusen Kabushiki Kaisha 8473 SBI Holdings,Inc. 2.Dividend yield (estimated) 3.50% 3. Constituent Issues (sort by local code) No. local code name 1 1414 SHO-BOND Holdings Co.,Ltd. 2 1605 INPEX CORPORATION 3 1878 DAITO TRUST CONSTRUCTION CO.,LTD. 4 1911 Sumitomo Forestry Co.,Ltd. 5 1925 DAIWA HOUSE INDUSTRY CO.,LTD. 6 1954 Nippon Koei Co.,Ltd. 7 2154 BeNext-Yumeshin Group Co. 8 2503 Kirin Holdings Company,Limited 9 2579 Coca-Cola Bottlers Japan Holdings Inc. 10 2914 JAPAN TOBACCO INC. 11 3003 Hulic Co.,Ltd. 12 3105 Nisshinbo Holdings Inc. 13 3191 JOYFUL HONDA CO.,LTD.
    [Show full text]
  • Kuraray/ Glsv Business
    EN Case No COMP/M.7115 - KURARAY/ GLSV BUSINESS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) in conjunction with Art 6(2) Date: 29/04/2014 In electronic form on the EUR-Lex website under document number 32014M7115 Office for Publications of the European Union L-2985 Luxembourg EUROPEAN COMMISSION Brussels, 29.4.2014 C(2014) 2946 final In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 PUBLIC VERSION concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a MERGER PROCEDURE general description. To the notifying party: Dear Sir/Madam, Subject: Case M.7115 – Kuraray/ GLSV Business Commission decision pursuant to Article 6(1)(b) in conjunction with Article 6(2) of Council Regulation No 139/20041 1. On 6 March 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ("the Merger Regulation") by which Kuraray Co., Ltd. ("Kuraray", Japan) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the Glass Laminating Solutions/Vinyls Business ("GLSV") of E. I. du Pont de Nemours and Company ("DuPont", USA), by way of purchase of assets. Kuraray and GLSV are hereinafter collectively referred to as "the Parties" while Kuraray individually is referred to as "Notifying Party". I. THE PARTIES AND THE OPERATION 2.
    [Show full text]
  • Product Japan : Food Processing Sector - Health and Functional Foods Company Profiles
    Foreign Agricultural Service GAIN Report Global Agriculture Information Network Approved by: Date: 07/23/99 Sarah D. Hanson GAIN Report #JA9087 U.S. Embassy Market Brief - Product Japan : Food Processing Sector - Health and Functional Foods Company Profiles This report was prepared by the USDA’s Foreign Agricultural Service for U.S. exporters of food and agricultural products. This information is in the public domain and may be reprinted without permission. Use of commercial or trade names does not imply approval nor constitute endorsement by USDA/FAS. Tokyo[JA1], JA GAIN Report #JA9087 Page 1 of 24 Company Name Amway Japan Product Sector(s) Health and Functional Food Address 1-8-1, Shimo-Meguro Number Of Employees 728 Meguro-ku, Tokyo 153-8686 Number of Factories Overseas Contact Phone Number 03-5434-8484 Fax Number 03-5434-4923 Email Web Page Address www.amway.co.jp/amway_japan/ Contact Person Masura Iwata Executive Driector, External Affairs and Public Relations Sales and Net Profits Main Suppliers Year Sales (Mil. \) Net Profits 1995 177,991 22,424 1996 212,195 25,130 1997 203,361 26,638 Key Products % of Total Company Profile and Strategies Home Care Products 9 Japanese corporation of nonstore sales operator Amway (US). Housewares 30 Registered sales personnel involved in direct sales of detergents, Personal Care 34 cosmetics, kitchenware and nutritional supplements. Nutritional Supplements 23 Others 4 Main Brands Triple X (vitamin and mineral supplement), Nutri Protein, Acerola C (vitamin supplement), Salmon-Omega 3, Hon-E-Cece, Ironics, Beta Carotene A, Wheat Germ E. Main Ingredients Vitamins, protein concentrates, iron concentrates, calcium concentrates, beta caroten, wheat germ.
    [Show full text]
  • May 11, 2011 Company Name: Terumo Corporation Representative: Yutaro Shintaku, President Code No.: 4543, TSE Section 1 Inquirie
    May 11, 2011 Company name: Terumo Corporation Representative: Yutaro Shintaku, President Code No.: 4543, TSE Section 1 Inquiries: Tetsuya Kumei, General Manager, Corporate Communication / IR Dept. Notice Concerning the Renewal of a Policy for Large-scale Acquisitions of Terumo Shares (Takeover Defense Measures) In the Board of Directors held on April 30, 2008, Terumo Corporation decided upon the Company’s basic policy regarding those who control decisions on the Company’s financial and business policies. Giving consideration to this policy, the Company also decided upon introduction of policy for large-scale acquisitions of the Company’s shares (hereinafter referred to as the “Current Plan”) as a means to prevent decisions on the Company’s financial and business policies from being controlled by an inappropriate party. The Current Plan was approved by shareholders in the 93rd Annual General Meeting of Shareholders held on June 27, 2008. The effective period of the Current Plan is until the conclusion of the final Annual General Meeting of Shareholders in the business year ending no more than three years from the time of the conclusion of the 93rd Annual General Meeting of Shareholders. Based on consideration of recent trends in debate on takeover defense measures including amendments of the law since the Current Plan was implemented and the Corporate Value Study Group established by the Ministry of Economy, Trade and Industry, the Company reaffirmed that the current policy should be maintained in the Board of Directors held on May 11, 2011, and passed a resolution to make revisions to the Current Plan required by amendments to the law (the revised plan is hereinafter referred to as the “Plan”) and renew the Current Plan in the form of the Plan as a means to prevent decisions on the Company’s financial and business policies from being controlled by an inappropriate party.
    [Show full text]
  • United Japan Growth Fund
    United Japan Growth Fund Semi Annual Report for the half year ended 30 June 2021 United Japan Growth Fund (Constituted under a Trust Deed in the Republic of Singapore) MANAGER UOB Asset Management Ltd Registered Address: 80 Raffles Place UOB Plaza Singapore 048624 Company Registration No. : 198600120Z Tel: 1800 22 22 228 DIRECTORS OF UOB ASSET MANAGEMENT LTD Lee Wai Fai Eric Tham Kah Jin PehKianHeng Thio Boon Kiat TRUSTEE State Street Trust (SG) Limited 168 Robinson Road #33-01, Capital Tower Singapore 068912 CUSTODIAN / ADMINISTRATOR / REGISTRAR State Street Bank and Trust Company, acting through its Singapore Branch 168 Robinson Road #33-01, Capital Tower Singapore 068912 AUDITOR PricewaterhouseCoopers LLP 7 Straits View, Marina One East Tower, Level 12 Singapore 018936 SUB-MANAGER Fukoku Capital Management, Inc. 1-3-1 Uchisaiwaicho Chiyoda-Ku Saiwai Building 3rd Floor Tokyo 100-0011, Japan -1- United Japan Growth Fund (Constituted under a Trust Deed in the Republic of Singapore) A) Fund Performance Since Inception 18 August 3yr 5yr 10 yr 1995 3mth 6mth 1yr Ann Ann Ann Ann Fund Performance/ % % % Comp Comp Comp Comp Benchmark Returns Growth Growth Growth Ret Ret Ret Ret United Japan Growth Fund -2.42 -2.27 16.23 3.68 5.17 4.75 2.57 Benchmark -0.24 3.01 20.29 6.73 10.16 8.13 0.60 Source: Morningstar. Note: The performance returns of the Fund are in Singapore Dollar based on a NAV-to-NAV basis with dividends and distributions reinvested, if any. The benchmark of the Fund: Aug 95 – Dec 04: Nikkei 225 Stock Average; Jan 05 – Dec 10: Topix; Jan 11 to Present: MSCI Japan Index.
    [Show full text]
  • FTSE Japan ESG Low Carbon Select
    2 FTSE Russell Publications 19 August 2021 FTSE Japan ESG Low Carbon Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country ABC-Mart 0.01 JAPAN Ebara 0.17 JAPAN JFE Holdings 0.04 JAPAN Acom 0.02 JAPAN Eisai 1.03 JAPAN JGC Corp 0.02 JAPAN Activia Properties 0.01 JAPAN Eneos Holdings 0.05 JAPAN JSR Corp 0.11 JAPAN Advance Residence Investment 0.01 JAPAN Ezaki Glico 0.01 JAPAN JTEKT 0.07 JAPAN Advantest Corp 0.53 JAPAN Fancl Corp 0.03 JAPAN Justsystems 0.01 JAPAN Aeon 0.61 JAPAN Fanuc 0.87 JAPAN Kagome 0.02 JAPAN AEON Financial Service 0.01 JAPAN Fast Retailing 3.13 JAPAN Kajima Corp 0.1 JAPAN Aeon Mall 0.01 JAPAN FP Corporation 0.04 JAPAN Kakaku.com Inc. 0.05 JAPAN AGC 0.06 JAPAN Fuji Electric 0.18 JAPAN Kaken Pharmaceutical 0.01 JAPAN Aica Kogyo 0.07 JAPAN Fuji Oil Holdings 0.01 JAPAN Kamigumi 0.01 JAPAN Ain Pharmaciez <0.005 JAPAN FUJIFILM Holdings 1.05 JAPAN Kaneka Corp 0.01 JAPAN Air Water 0.01 JAPAN Fujitsu 2.04 JAPAN Kansai Paint 0.05 JAPAN Aisin Seiki Co 0.31 JAPAN Fujitsu General 0.01 JAPAN Kao 1.38 JAPAN Ajinomoto Co 0.27 JAPAN Fukuoka Financial Group 0.01 JAPAN KDDI Corp 2.22 JAPAN Alfresa Holdings 0.01 JAPAN Fukuyama Transporting 0.01 JAPAN Keihan Holdings 0.02 JAPAN Alps Alpine 0.04 JAPAN Furukawa Electric 0.03 JAPAN Keikyu Corporation 0.02 JAPAN Amada 0.01 JAPAN Fuyo General Lease 0.08 JAPAN Keio Corp 0.04 JAPAN Amano Corp 0.01 JAPAN GLP J-REIT 0.02 JAPAN Keisei Electric Railway 0.03 JAPAN ANA Holdings 0.02 JAPAN GMO Internet 0.01 JAPAN Kenedix Office Investment Corporation 0.01 JAPAN Anritsu 0.15 JAPAN GMO Payment Gateway 0.01 JAPAN KEWPIE Corporation 0.03 JAPAN Aozora Bank 0.02 JAPAN Goldwin 0.01 JAPAN Keyence Corp 0.42 JAPAN As One 0.01 JAPAN GS Yuasa Corp 0.03 JAPAN Kikkoman 0.25 JAPAN Asahi Group Holdings 0.5 JAPAN GungHo Online Entertainment 0.01 JAPAN Kinden <0.005 JAPAN Asahi Intecc 0.01 JAPAN Gunma Bank 0.01 JAPAN Kintetsu 0.03 JAPAN Asahi Kasei Corporation 0.26 JAPAN H.U.
    [Show full text]